Exit In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia***Poster 4 Post-assessment*** In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing score of at least 75% on this post-survey, as well as complete the evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. There is no fee to participate in this activity. Question Title * 1. What are your credentials? MD/DO NP PA Nurse PharmD Other (please specify) Question Title * 2. What is your area of specialty? Hematology Oncology Other (please specify) Question Title * 3. How many years have you been in practice? <1 1-10 11-20 >21 Question Title * 4. Please select the option that best describes your practice setting: Academic medical center Community hospital or medical center VA, DOD, or other government Managed care Research Pharmaceutical industry Question Title * 5. Of the patients you will see in the next month, about how many will benefit from the information you learned today? Question Title * 6. After participating in this activity, how confident are you in the management of patients with ALL in your practice? Very confident Confident Neutral Little confidence No confidence Very confident Confident Neutral Little confidence No confidence Question Title * 7. In the 3 clinical trials reviewed (SWOG 1318, EWALL-INO and INITIAL-1), which of the following outcomes were observed in elderly patients with Ph-ALL? Low rate of secondary malignancies Low rate of late relapses Low rate of induction deaths Low rate of complete response Question Title * 8. Which of the following interventions was evaluated in attempt to improve both the efficacy and tolerability of therapy in the SWOG1318 study in elderly patients with Ph-ALL? Omission of chemotherapy in induction and consolidation Omission of maintenance chemotherapy Dose reduction of chemotherapy in induction and consolidation Dose reduction of blinatumomab by 50% Evaluation FormIn order to receive a CME/CE certificate for your participation in this activity, please complete this form in its entirety. Question Title * 9. How committed are you to making changes in your practice based on your participation in this activity? Very committed Committed Neutral Not committed I do not plan to make changes Very committed Committed Neutral Not committed I do not plan to make changes If not committed or do not plan to make changes, please indicate reason Question Title * 10. Which of the following best describes the impact of this activity on your performance? I gained new strategies/skills/information I can apply to my area of practice I need more information before I can change my practice My practice is already consistent with the information presented This activity will not change my practice Question Title * 11. Which new strategies/skills/information will you apply to your area of practice? Recognize the role of inotuzumab ozogamicin in the treatment of newly diagnosed CD22+, Ph-neg ALL based on the EWALL-INO study Identify the utility of inotuzumab ozogamicin in the treatment of patients aged 56 years and older with ALL based on the INITIAL-1 study Position blinatumomab as monotherapy followed by POMP maintenance in older adults with Ph-, B-cell ALL based on SWOG 1318 study Question Title * 12. What barriers do you see to making changes in your practice? Lack of knowledge regarding evidence-based strategies Lack of convincing evidence to warrant change Lack of time/resources to consider change Insurance, reimbursement or legal issues Conflicting guidelines or evidence Patient compliance and/or patient resource barriers Other (please specify) Question Title * 13. After participating in today’s activity, I am now better able to: Strongly agree Agree Neutral Disagree Strongly disagree Review recently presented clinical trial data in older adults with treatment-naïve, Philadelphia chromosome negative, acute lymphoblastic leukemia Review recently presented clinical trial data in older adults with treatment-naïve, Philadelphia chromosome negative, acute lymphoblastic leukemia Strongly agree Review recently presented clinical trial data in older adults with treatment-naïve, Philadelphia chromosome negative, acute lymphoblastic leukemia Agree Review recently presented clinical trial data in older adults with treatment-naïve, Philadelphia chromosome negative, acute lymphoblastic leukemia Neutral Review recently presented clinical trial data in older adults with treatment-naïve, Philadelphia chromosome negative, acute lymphoblastic leukemia Disagree Review recently presented clinical trial data in older adults with treatment-naïve, Philadelphia chromosome negative, acute lymphoblastic leukemia Strongly disagree Question Title * 14. The following faculty presenter effectively presented the material: Strongly agree Agree Neutral Disagree Strongly disagree Lori Muffly, MD, MS Lori Muffly, MD, MS Strongly agree Lori Muffly, MD, MS Agree Lori Muffly, MD, MS Neutral Lori Muffly, MD, MS Disagree Lori Muffly, MD, MS Strongly disagree Marlise Luskin, MD, MSCE Marlise Luskin, MD, MSCE Strongly agree Marlise Luskin, MD, MSCE Agree Marlise Luskin, MD, MSCE Neutral Marlise Luskin, MD, MSCE Disagree Marlise Luskin, MD, MSCE Strongly disagree Question Title * 15. The content presented: Strongly agree Agree Neutral Disagree Strongly disagree Enhanced my current knowledge base Enhanced my current knowledge base Strongly agree Enhanced my current knowledge base Agree Enhanced my current knowledge base Neutral Enhanced my current knowledge base Disagree Enhanced my current knowledge base Strongly disagree Addressed my most pressing questions Addressed my most pressing questions Strongly agree Addressed my most pressing questions Agree Addressed my most pressing questions Neutral Addressed my most pressing questions Disagree Addressed my most pressing questions Strongly disagree Promoted improvements or quality in health care Promoted improvements or quality in health care Strongly agree Promoted improvements or quality in health care Agree Promoted improvements or quality in health care Neutral Promoted improvements or quality in health care Disagree Promoted improvements or quality in health care Strongly disagree Was scientifically rigorous and evidence based Was scientifically rigorous and evidence based Strongly agree Was scientifically rigorous and evidence based Agree Was scientifically rigorous and evidence based Neutral Was scientifically rigorous and evidence based Disagree Was scientifically rigorous and evidence based Strongly disagree Avoided commercial bias or influence Avoided commercial bias or influence Strongly agree Avoided commercial bias or influence Agree Avoided commercial bias or influence Neutral Avoided commercial bias or influence Disagree Avoided commercial bias or influence Strongly disagree Question Title * 16. If you indicated that you perceived commercial bias or influence, please describe: Question Title * 17. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice? Question Title * 18. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related ALL: Question Title * 19. Please let us know who you are so we can connect your responses to your pre-test & application to claim CME credit. First & Last Name Degree/Credentials ZIP/Postal Code Country Email Address Question Title * 20. I certify that I have participated in the continuing education activity entitled, “In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia" and claim 0.5 AMA PRA Category 1 CreditTM. Yes No Done
